George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

14 Apr 2020 16:37

RNS Number : 6322J
Circassia Pharmaceuticals Plc
14 April 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

CIRCASSIA PHARMACEUTICALS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Harwood Capital LLP (as investment adviser/manager) and 1. Oryx International Growth Fund Limited 2. Harwood Capital LLP and 3. North Atlantic Smaller Companies Investment Trust plc

City and country of registered office (if applicable)

1. Guernsey

2. & 3. London, United Kingdom

 

4. Full name of shareholder(s) (if different from 3.)v

Name

1. Oryx International Growth Fund Limited

2. Harwood Capital LLP

3. North Atlantic Smaller Companies Investment Trust plc

 

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

9th April 2020

6. Date on which issuer notified (DD/MM/YYYY):

14th April 2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

1. 40,000,000

2. 70,000

3, 1,200,000

 

 

 

1. 10.66%

2. 0.02%

3. 0.32%

 

375,210,543

Position of previous notification (if

applicable)

1. 35,000,000

2. 70,000

 

 

 

 9.33%

 0.02%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJVD3B281.

1.

2.

3.

 

40,000,000

70,000

1,200,000

 

 

10.66%

0.02%

0.32%

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

41,270,000

11.00%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

10.66

0

10.66

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

Oryx International Growth Fund Ltd

 

 

 

 

 

 

 

Christopher Harwood Bernard Mills

0.02

0

0.02

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

 

 

 

 

Christopher Harwood Bernard Mills

 0.32

 

0.32

Harwood Capital Management Ltd

 

 

 

Harwood Capital LLP

 

 

 

North Atlantic Smaller Companies Investment Trust plc

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

Oxford, UK

Date of completion

14th April 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUSOVRRVUSAAR
Date   Source Headline
18th Jan 20192:22 pmRNSBlock listing Interim Review
4th Jan 20191:48 pmRNSResult of General Meeting
4th Jan 20197:00 amRNSGeneral Meeting Business Update
31st Dec 20187:00 amRNSTotal Voting Rights
27th Dec 20187:00 amRNSHolding(s) in Company
17th Dec 20187:00 amRNSListing Rule 9.6.14(R) Disclosure
11th Dec 201812:10 pmRNSOption exercised for Tudorza from AstraZeneca
10th Dec 20185:59 pmRNSPosting of Shareholder Circular
10th Dec 201812:59 pmRNSProposed admission to trading on AIM
30th Nov 20187:00 amRNSTotal Voting Rights
31st Oct 20182:13 pmRNSTotal Voting Rights
25th Oct 20183:00 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSTotal Voting Rights
27th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
7th Sep 201811:36 amRNSNotice of Interim Results and Broker Appointment
3rd Sep 201812:15 pmRNSTotal Voting Rights
16th Aug 20184:25 pmRNSDirector Declaration
13th Aug 20187:00 amRNSRegulatory Application
31st Jul 20187:00 amRNSTotal Voting Rights
18th Jul 20184:14 pmRNSHolding(s) in Company
18th Jul 20184:12 pmRNSHolding(s) in Company
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 20181:52 pmRNSIssue of Equity and Total Voting Rights
16th Jul 20183:28 pmRNSResult of AGM
2nd Jul 20187:00 amRNSBlock listing Interim Review
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 201812:23 pmRNSPublication of Circular
11th Jun 20184:20 pmRNSHolding(s) in Company
4th Jun 20184:18 pmRNSDirector/PDMR Shareholding
4th Jun 20184:15 pmRNSDirector/PDMR Shareholding
4th Jun 20184:14 pmRNSDirector/PDMR Shareholding
1st Jun 20187:00 amRNSUS Filing of Duaklir NDA & Tudorza Supplement NDA
31st May 20187:00 amRNSTotal Voting Rights
30th May 201812:05 pmRNSResult of AGM
22nd May 20187:00 amRNSPositive Data Presented at 2018 ATS Conference
18th May 201810:57 amRNSBlock listing Interim Review
14th May 20183:37 pmRNSHolding(s) in Company
30th Apr 20185:08 pmRNSTotal Voting Rights Update
27th Apr 20184:45 pmRNSAnnual Financial Report and Notice of AGM
26th Apr 20185:46 pmRNSHolding(s) in Company
26th Apr 20185:46 pmRNSHolding(s) in Company
24th Apr 20187:00 amRNSFinal Results
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
12th Apr 20187:00 amRNSNotice of Results
29th Mar 20187:00 amRNSTotal Voting Rights
16th Mar 20184:40 pmRNSSecond Price Monitoring Extn
16th Mar 20184:35 pmRNSPrice Monitoring Extension
28th Feb 20182:01 pmRNSTotal Voting Rights
13th Feb 20187:00 amRNSDirectorate Change
8th Feb 20187:00 amRNSReceives Innovative Tech Contract from Vizient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.